Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 2 of 2 entries
Sorted by: Best Match Show Resources per page
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.

Targeted oncology

Ramanathan RK, Von Hoff DD, Eskens F, Blumenschein G, Richards D, Genvresse I, Reschke S, Granvil C, Skubala A, Peña C, Mross K.
PMID: 33108585
Target Oncol. 2020 Dec;15(6):803. doi: 10.1007/s11523-020-00762-6.

The article Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.

Cite
Ramanathan RK, Von Hoff DD, Eskens F, et al. Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer. Target Oncol. 2020;15(6):803doi: 10.1007/s11523-020-00762-6.
Ramanathan, R. K., Von Hoff, D. D., Eskens, F., Blumenschein, G., Richards, D., Genvresse, I., Reschke, S., Granvil, C., Skubala, A., Peña, C., & Mross, K. (2020). Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer. Targeted oncology, 15(6), 803. https://doi.org/10.1007/s11523-020-00762-6
Ramanathan, Ramesh K, et al. "Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer." Targeted oncology vol. 15,6 (2020): 803. doi: https://doi.org/10.1007/s11523-020-00762-6
Ramanathan RK, Von Hoff DD, Eskens F, Blumenschein G, Richards D, Genvresse I, Reschke S, Granvil C, Skubala A, Peña C, Mross K. Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer. Target Oncol. 2020 Dec;15(6):803. doi: 10.1007/s11523-020-00762-6. PMID: 33108585; PMCID: PMC7701068.
Copy Download .nbib Format: NLM
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer.

Targeted oncology

Ramanathan RK, Von Hoff DD, Eskens F, Blumenschein G, Richards D, Genvresse I, Reschke S, Granvil C, Skubala A, Peña C, Mross K.
PMID: 32314268
Target Oncol. 2020 Apr;15(2):163-174. doi: 10.1007/s11523-020-00714-0.

BACKGROUND: Dual inhibition of PI3K and MAPK signaling is conceptually a promising anticancer therapy.OBJECTIVE: This phase 1b trial investigated the safety, maximum tolerated dose (MTD), recommended phase II dose, pharmacokinetics, tumor response, fluorodeoxyglucose positron emission tomography (FDG-PET) pharmacodynamics, and...

Cite
Ramanathan RK, Von Hoff DD, Eskens F, et al. Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer. Target Oncol. 2020;15(2):163-174doi: 10.1007/s11523-020-00714-0.
Ramanathan, R. K., Von Hoff, D. D., Eskens, F., Blumenschein, G., Richards, D., Genvresse, I., Reschke, S., Granvil, C., Skubala, A., Peña, C., & Mross, K. (2020). Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer. Targeted oncology, 15(2), 163-174. https://doi.org/10.1007/s11523-020-00714-0
Ramanathan, Ramesh K, et al. "Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer." Targeted oncology vol. 15,2 (2020): 163-174. doi: https://doi.org/10.1007/s11523-020-00714-0
Ramanathan RK, Von Hoff DD, Eskens F, Blumenschein G, Richards D, Genvresse I, Reschke S, Granvil C, Skubala A, Peña C, Mross K. Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer. Target Oncol. 2020 Apr;15(2):163-174. doi: 10.1007/s11523-020-00714-0. PMID: 32314268; PMCID: PMC7591420.
Copy Download .nbib Format: NLM
Showing 1 to 2 of 2 entries